Also on August 17, 2017, the FDA approved Lynparza (olaparib; from AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a complete or partial response to platinum-based chemotherapy.
On the same day, the FDA also approved a tablet form of Lynparza for patients with deleterious or suspected deleterious germline BRCA mutation–positive advanced ovarian cancer who have received 3 or more previous chemotherapies.
The most common side effects with Lynparza include anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, constipation, stomatitis, headache, dysgeusia, dyspepsia, decreased appetite, arthralgia, or myalgia.